The publisher explores Incyte’s prescription pharmaceutical performance and outlook over 2019–29.
Snapshot
Model updates (5 May 2020)
Model updates (13 February 2020)
Model updates (5 November 2019)
Model updates (12 July 2019)
Snapshot
- Overview – Incyte continues to be driven by robust Jakafi sales.
- Key themes: [1] Incyte continues to grow Jakafi volumes at a strong pace, with supplemental approvals and label expansions adding to the lifecycle management of the drug [2] Jakafi patent expiration in 2028 is a key event for Incyte as the drug will comprise a significant majority of company revenues [3] Royalties and collaboration revenues will substantially bolster Incyte over the forecast period.
Model updates (5 May 2020)
- Jakafi forecast adjusted higher due to continued uptake in GVHD
- Pemigatinib name changed to Pemazyre; forecast pulled forward due to earlier-than-anticipated approval for cholangiocarcinoma
- Tafasitamab forecast added due to closing of licensing agreement with MorphoSys.
Model updates (13 February 2020)
- Jakafi forecast adjusted higher due to continued growth in MF, strong growth in PV, and an above-expectations launch in steroid-refractory acute GVHD.
Model updates (5 November 2019)
- Jakafi forecast adjusted higher due to continued growth in MF, strong growth in PV, and an above-expectations launch in steroid-refractory acute GVHD.
Model updates (12 July 2019)
- Jakafi sales adjusted higher to account for continued sales momentum in myelofibrosis and polycythemia vera. Added forecast for recently approved indication of steroid-refractory acute graft-versus-host disease, assuming an immediate launch in the US
- Epacadostat removed from forecast after failed Phase III (ECHO-301/KEYNOTE-252) trial in melanoma
- Ruxolitinib cream forecast added
- Pemigatinib forecast added.
Table of Contents
Company Background
Recent Earnings Review
Company Forecast
Company Profile
Clinical Trial Overview
